Millennium Management
CURX

Millennium Management’s Curanex Pharmaceuticals CURX Stock Holding History

Millennium Management’s Portfolio CURX Stock Details CURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,154
Closed -$13.8K – 6633
2025
Q3 		$13.8K Buy
+19,154
New +$86.7K ﹤0.01% 5883

Other funds holding CURX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Millennium Management's CURX Position: Q4 2025 in Review

Millennium Management sold out of Curanex Pharmaceuticals (CURX) in Q4 2025, closing a stake of 19,154 shares — an estimated $13.8K sold.

Millennium Management first reported a position in CURX in Q3 2025 and held it in 1 quarter. The position peaked at $13.8K in Q3 2025. 11 funds tracked by Wall St. Rank hold CURX as of Q4 2025.

  • Millennium Management reported no remaining Curanex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Millennium Management sold 19,154 Curanex Pharmaceuticals shares in Q4 2025, an estimated $13.8K.
  • Millennium Management first reported a position in Curanex Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Millennium Management's Curanex Pharmaceuticals position peaked at $13.8K in Q3 2025.
  • 11 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q4 2025.

Based on Millennium Management's 13F filing for Q4 2025, filed 17 Feb 2026.